Last updated: August 20, 2026
Disopyramide phosphate is an established Class IA antiarrhythmic with limited competition, low product differentiation, and a small but clinically important market. The strongest commercial opportunities are formulation-led: modified-release capsules, liquid dosage forms, patient-specific compounding, and excipient systems that improve swallowing, dose uniformity, stability, and manufacturing efficiency. The main development constraints are cardiac safety, anticholinergic effects, narrow therapeutic use, and the need to demonstrate pharmaceutical equivalence or clinical performance under the applicable FDA pathway.
What is the commercial status of disopyramide phosphate?
Disopyramide phosphate is the salt form used in oral pharmaceutical products for the treatment of documented ventricular arrhythmias. In the United States, the reference products have been marketed under the Norpace and Norpace CR names. The immediate-release product is supplied in 100 mg and 150 mg capsules; controlled-release presentations have also been marketed in 150 mg strength.[1]
Disopyramide has a narrow therapeutic window. Its pharmacology creates formulation requirements that differ from those of conventional maintenance drugs:
- Dose accuracy is critical because excessive exposure can increase anticholinergic toxicity, hypotension, conduction abnormalities, and proarrhythmic risk.
- Renal function affects exposure and dosing.
- Immediate-release and modified-release products are not interchangeable solely on the basis of label strength.
- Excipients that materially change dissolution, gastric emptying, or intestinal release can affect clinical performance.
- Patients may include older adults who have difficulty swallowing capsules or who require individualized dose adjustment.
The product is primarily a mature-generic opportunity rather than a new chemical entity opportunity. Commercial value depends on reliable supply, dosage-form convenience, lower manufacturing cost, and access to underserved channels.
What patents protect disopyramide phosphate products?
The original compound and early formulation rights for disopyramide phosphate are old and are not expected to create a meaningful current United States composition-of-matter barrier. The relevant commercial question is whether any current product-specific formulation or method-of-use patents are listed in the FDA Orange Book.
The Orange Book should be checked by active ingredient, proprietary name, and applicant for current listed patents and exclusivity information.[2] Based on the age of disopyramide products and their established generic availability, the principal competitive risk is unlikely to be an active basic patent. The more relevant barriers are:
| IP category |
Likely current significance |
Commercial implication |
| Composition-of-matter patent |
Low |
Historical protection is expected to have expired |
| Conventional capsule formulation |
Low |
Usually difficult to sustain as enforceable exclusivity |
| Modified-release formulation |
Moderate |
Could protect release architecture, coating, matrix, or multiparticulates |
| Manufacturing process |
Low to moderate |
May create know-how advantages even without blocking patents |
| Method of use |
Low to moderate |
May matter only if tied to a narrow, non-obvious patient population |
| Device or packaging |
Low |
May support differentiation but rarely blocks generic entry |
| Regulatory exclusivity |
Low |
Products are mature and generally beyond ordinary exclusivity periods |
A developer should avoid assuming that an old drug has no relevant IP. A modified-release product can have separate formulation patents even when the active ingredient is fully off-patent. Patent clearance should cover U.S. and foreign family members, abandoned applications, terminal disclaimers, prosecution history, and freedom to operate around coating polymers, pellet technologies, and capsule manufacturing.
When does disopyramide phosphate lose exclusivity?
Disopyramide phosphate has already lost the core exclusivity associated with its original approval. The commercial market is therefore governed primarily by generic approval, manufacturing capability, product availability, and physician familiarity.
The most relevant FDA pathways are:
Abbreviated New Drug Application
An ANDA is the standard route for a therapeutically equivalent immediate-release generic when the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The dosage form, strength, route, labeling, and release characteristics must match the applicable reference product.[3]
For a conventional immediate-release capsule, the development program would normally focus on:
- Assay and content uniformity
- Dissolution across multiple media and pH conditions
- Impurity and degradation profiling
- Comparative bioavailability
- Stability under ICH conditions
- Capsule shell compatibility
- Manufacturing control of fill weight and blend uniformity
505(b)(2) application
A 505(b)(2) application may be more suitable for a product that changes the dosage form, release profile, route, or excipient system in a manner that cannot rely entirely on an ANDA reference product. Examples include:
- Oral solution
- Modified-release capsule
- Sprinkle formulation
- Pediatric liquid
- Novel multiparticulate delivery system
- Product with clinically meaningful dosing flexibility
A 505(b)(2) strategy can create a differentiated product, but it may require additional clinical or pharmacokinetic evidence. The regulatory value depends on whether the change solves a defined clinical problem rather than merely changing inactive ingredients.
What excipients are suitable for disopyramide phosphate capsules?
The preferred excipient system depends on whether the product is immediate release or modified release. A conventional capsule should prioritize rapid, reproducible drug release and low variability.
Immediate-release capsule strategy
A practical immediate-release formulation may use:
- Microcrystalline cellulose or dibasic calcium phosphate as a diluent
- Crospovidone, croscarmellose sodium, or sodium starch glycolate as a disintegrant
- Colloidal silicon dioxide as a glidant
- Magnesium stearate or sodium stearyl fumarate as a lubricant
- Hard gelatin or hydroxypropyl methylcellulose capsule shells
The salt's particle size, bulk density, electrostatic behavior, and moisture sensitivity should determine the process design. Disopyramide phosphate may not require a complex solubilization system, but the developer should establish dissolution robustness across pH conditions rather than rely on nominal aqueous solubility.
The main excipient risks are:
- Excessive lubricant concentration or blending time, which can slow dissolution.
- Segregation caused by differences in particle size and density.
- Moisture-driven changes in flow, compactability, or capsule fill.
- Over-disintegration, which can create powder leakage or poor patient acceptability.
- Capsule-shell brittleness or cross-linking under unfavorable storage conditions.
A direct-blend capsule may offer the lowest cost, but roller compaction or wet granulation can improve content uniformity if the formulation has poor flow or low-dose blend risks. Because the marketed strengths are relatively high, a low-dose potency problem is less severe than with highly potent drugs, but blend uniformity remains important when multiple strengths use a common formulation platform.
Modified-release capsule strategy
A controlled-release product has greater commercial differentiation but also greater regulatory and technical risk. Candidate platforms include:
- Hydrophilic matrix granules
- Ethylcellulose-coated pellets
- Ammonio methacrylate copolymer-coated multiparticulates
- Hypromellose matrix systems
- Ion-exchange resin complexes
- Osmotic or membrane-controlled systems
Multiparticulates are attractive because they can provide more consistent gastrointestinal distribution and reduce the risk of dose dumping compared with a single-unit matrix. They also support capsule opening and sprinkling if the coating remains intact and the label permits that administration method.
A modified-release formulation should be evaluated for:
- Alcohol-induced dose dumping
- Food effects
- Acid-to-buffer transition
- Crushing or chewing damage
- Capsule opening and sprinkle administration
- Inter-patient variability
- Renal impairment exposure
- Stability of the release-controlling polymer
- In vitro-in vivo correlation
The commercial rationale must be specific. A modified-release product can reduce dosing frequency, but the benefit may be limited if the product is used in a small specialist population. Development costs should be matched against expected institutional, retail, and specialty-pharmacy demand.
What formulations are protected by excipient and delivery-system IP?
The most defensible formulation IP would usually relate to a defined technical result rather than a generic list of excipients. Potential claim areas include:
- A disopyramide phosphate multiparticulate capsule with a specified release profile
- A pH-independent release system
- A formulation that limits alcohol-induced release acceleration
- A stable oral solution with controlled pH and low precipitation
- A sprinkle product that maintains bioavailability after capsule opening
- A preservative-free unit-dose liquid
- A composition with defined impurity limits after accelerated storage
- A manufacturing process that produces consistent coating weight gain and dissolution
A formulation patent based only on substituting one conventional diluent for another is vulnerable to obviousness challenges. Stronger protection would combine composition ranges, dissolution parameters, process controls, and demonstrated pharmacokinetic or stability advantages.
Freedom-to-operate review should include excipient suppliers' proprietary coating technologies, resin systems, capsule-shell technologies, and controlled-release platform licenses. Excipients themselves are generally not patent-free merely because they are widely used. Specific grades, combinations, processing methods, and commercial delivery systems can have separate rights.
What are the best commercial opportunities for disopyramide phosphate?
1. Reliable immediate-release generic supply
The most straightforward opportunity is a high-quality generic capsule with dependable availability. Mature antiarrhythmic products can experience supply shortages because annual volume is modest and manufacturing economics are less attractive than for high-volume drugs.
A supplier can compete through:
- Dual-source API qualification
- High-yield capsule filling
- Common-platform manufacturing across strengths
- Low minimum order quantities
- Hospital and specialty-pharmacy contracts
- Inventory buffers for low-volume products
This strategy has limited product differentiation but can generate value where competitors have intermittent supply or high acquisition costs.
2. Modified-release replacement
A controlled-release capsule may provide a differentiated alternative for patients requiring less frequent dosing. The key commercial question is whether a reference modified-release product remains actively marketed and whether the proposed product can establish bioequivalence or requires a 505(b)(2) clinical program.
The opportunity is strongest if the product can demonstrate:
- Reduced dosing frequency
- Comparable overall exposure
- Lower peak-to-trough fluctuation
- Acceptable food-effect behavior
- Practical capsule size
- Lower pill burden
3. Oral liquid and extemporaneous-compounding replacement
A standardized oral liquid could address patients who cannot swallow capsules, including older adults, patients with feeding tubes, and selected pediatric or neurologic populations. This is a higher-value formulation opportunity because it may replace variable pharmacy compounding.
Important excipient choices include:
- Aqueous versus cosolvent-based vehicle
- Buffer system
- Sweetener and flavor
- Suspending agent
- Preservative or preservative-free packaging
- Low-sorbitol or sugar-free design
- Compatibility with enteral feeding tubes
- Multi-dose versus unit-dose packaging
The formulation must control precipitation, pH drift, microbial growth, adsorption to administration equipment, and dose uniformity after storage. A 505(b)(2) product could be commercially differentiated if the liquid has validated stability and administration advantages.
4. Geriatric and dysphagia-focused product
A capsule that can be opened and sprinkled on soft food may address a specific administration problem. The formulation must maintain release performance after capsule opening and avoid powder loss. Immediate-release granules are easier to develop than controlled-release pellets, but the label must clearly define permitted administration.
A smaller capsule, lower-friction shell, or easier-to-open packaging may support commercial differentiation without materially changing the drug product.
5. Specialty and hospital supply
Disopyramide is used in a narrow therapeutic setting, including selected ventricular arrhythmia and inherited arrhythmia management. A manufacturer with established cardiology, hospital, or specialty-pharmacy distribution can capture value through service reliability rather than broad consumer marketing.
What FDA regulatory status and Orange Book issues matter?
The principal regulatory tasks are confirmation of the current reference listed drug, identification of active strengths and dosage forms, and review of any Orange Book patent or exclusivity listings. FDA's Orange Book identifies approved drug products, therapeutic-equivalence evaluations, patents, and exclusivity information.[2]
For an immediate-release generic, the developer should assess:
- Whether the reference listed drug remains available
- Whether the relevant reference is Norpace, Norpace CR, or another listed product
- Whether the proposed capsule has the same release characteristics
- Whether the reference product has an active therapeutic-equivalence code
- Whether any product-specific patent certifications are required
- Whether a Paragraph IV certification is relevant
A Paragraph IV challenge would be relevant only if an active listed patent covers the reference product. Given the age of disopyramide phosphate, Paragraph IV activity is more likely to arise around a later modified-release formulation than around the underlying active ingredient.
Which companies are challenging disopyramide phosphate patents?
No material current Paragraph IV litigation landscape can be stated without a contemporaneous Orange Book and court-docket review. For this mature product, the more probable competitive pattern is generic supply by approved manufacturers rather than a major active patent dispute.
Patent litigation risk should be evaluated separately for:
- Immediate-release capsules
- Controlled-release capsules
- Oral liquids
- Sprinkle formulations
- Manufacturing processes
- Method-of-use claims
A product can face commercial competition without patent litigation if multiple ANDA holders are approved or if the market is supplied through authorized generics and contract manufacturers.
How strong is the disopyramide phosphate patent estate?
The core patent estate is weak from a life-cycle perspective because the drug is old and genericized. A new entrant's strongest defensible position would likely come from formulation and process claims supported by measurable performance advantages.
| Estate component |
Relative strength |
Reason |
| Active ingredient |
Low |
Mature, established molecule |
| Phosphate salt |
Low |
Longstanding pharmaceutical form |
| Immediate-release capsule |
Low |
Conventional dosage form |
| Modified release |
Moderate |
Technical complexity can support narrower claims |
| Oral liquid |
Moderate |
Stability and administration claims may be differentiated |
| Sprinkle formulation |
Moderate |
Administration and release data may support claims |
| Manufacturing process |
Moderate |
Know-how may be difficult to replicate |
| Method of use |
Low to moderate |
Limited market and potential obviousness issues |
The commercial value of a patent portfolio will depend less on claim breadth than on whether it protects a product with a defined channel advantage and limited substitution.
What generic entry risks exist for disopyramide phosphate?
Generic entry risk is structurally high because the active ingredient is mature and the conventional capsule is relatively simple. At the same time, market supply risk can be high because low demand may discourage multiple manufacturers.
The relevant scenario is therefore asymmetric:
- New conventional generic entry can reduce price and share.
- Manufacturing discontinuation can create shortages and increase the value of dependable supply.
- A differentiated liquid or modified-release product can preserve pricing better than a standard capsule.
- Hospital buyers may prioritize continuity and regulatory compliance over the lowest unit price.
- A formulation with a unique dosage form may avoid direct substitution, but only if it obtains the appropriate regulatory status.
How does disopyramide phosphate compare with competing antiarrhythmics?
Disopyramide competes clinically with other antiarrhythmics, but its commercial competition is not limited to drugs in the same pharmacologic class. Amiodarone, sotalol, flecainide, propafenone, quinidine, and mexiletine may be considered in different clinical contexts. Their formulations, safety profiles, and prescribing patterns differ.
| Product |
Primary commercial distinction |
Formulation opportunity |
| Disopyramide phosphate |
Mature Class IA agent, narrow specialist use |
Modified release, oral liquid, reliable supply |
| Quinidine |
Older Class IA agent with multiple dosage forms |
Liquid and specialty access |
| Flecainide |
Class IC alternative in selected patients |
Less need for liquid differentiation |
| Sotalol |
Antiarrhythmic and beta-blocking activity |
Dose titration and renal-use considerations |
| Amiodarone |
Broad antiarrhythmic use, significant long-term toxicity |
Stronger volume but different risk profile |
| Propafenone |
Class IC agent with beta-blocking effects |
Immediate- and extended-release competition |
Disopyramide's opportunity is niche positioning, not mass-market substitution. Its value increases when the product solves a formulation or supply problem that competing therapies do not address.
What revenue exposure should investors and licensors assess?
Revenue exposure should be modeled using product-specific sales data rather than broad antiarrhythmic market estimates. Key variables are:
- Annual treated-patient population
- Average daily dose
- Immediate-release versus modified-release share
- Generic price erosion
- Number of approved manufacturers
- Hospital and specialty-pharmacy concentration
- Shortage history
- API cost and minimum batch size
- Regulatory development cost
- Commercial launch requirements
- Probability of substitution by other antiarrhythmics
For a standard generic capsule, the market may support only a small number of economically viable manufacturers. A liquid or modified-release product can increase net price per patient but requires more development evidence and may serve a smaller population.
Key Takeaways
- Disopyramide phosphate is a mature, genericized Class IA antiarrhythmic with limited core patent protection.
- Immediate-release capsules offer the lowest regulatory and technical risk but face strong price competition.
- Modified-release capsules, oral liquids, sprinkle products, and geriatric-friendly presentations provide the clearest formulation-led opportunities.
- Excipient selection must protect dissolution, dose uniformity, stability, and administration performance.
- A 505(b)(2) strategy may be appropriate for a clinically meaningful dosage-form change.
- The commercial opportunity is driven by specialist demand, reliable supply, and formulation convenience rather than broad market growth.
- Current Orange Book listings, therapeutic-equivalence codes, and court records should control any final Paragraph IV or freedom-to-operate conclusion.
FAQs
Can disopyramide phosphate be formulated as an oral solution?
Yes. An oral solution or suspension could address dysphagia, feeding-tube administration, and pharmacy-compounding needs. The formulation must control precipitation, microbial stability, pH, dose uniformity, and compatibility with administration devices.
Is a disopyramide phosphate extended-release capsule commercially attractive?
Potentially. The opportunity depends on evidence that reduced dosing frequency or lower peak-to-trough variation provides a practical advantage over immediate-release capsules. Development and bioequivalence requirements are materially more complex.
Which excipient is best for immediate-release disopyramide capsules?
No single excipient is universally optimal. Microcrystalline cellulose or dibasic calcium phosphate can support fill performance, while crospovidone or croscarmellose sodium can promote disintegration. Final selection should be based on dissolution, stability, flow, and capsule-filling data.
Does disopyramide phosphate have biosimilar risk?
No. Disopyramide phosphate is a small-molecule drug, so the relevant competitors are generic products, not biosimilars.
Can a new disopyramide formulation receive market exclusivity?
A new formulation may qualify for regulatory exclusivity or patent protection if it meets applicable statutory requirements and provides a qualifying change. The availability and duration of exclusivity depend on the FDA pathway, product features, and any applicable patent listings.
References
-
Pfizer Inc. (n.d.). Norpace (disopyramide phosphate) capsules prescribing information. U.S. Food and Drug Administration labeling archive.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2018). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
-
U.S. Food and Drug Administration. (n.d.). 505(b)(2) applications. https://www.fda.gov/drugs/types-applications/505b2-application
-
U.S. National Library of Medicine. (n.d.). Disopyramide phosphate drug labeling and clinical information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
